AR043537A1 - Derivados azabiciclicos de piridiloximetilo y bencisoxazol - Google Patents
Derivados azabiciclicos de piridiloximetilo y bencisoxazolInfo
- Publication number
- AR043537A1 AR043537A1 ARP040100770A ARP040100770A AR043537A1 AR 043537 A1 AR043537 A1 AR 043537A1 AR P040100770 A ARP040100770 A AR P040100770A AR P040100770 A ARP040100770 A AR P040100770A AR 043537 A1 AR043537 A1 AR 043537A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- groups
- substituted
- cycloalkyl
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- -1 aminomethylpyridyloxymethyl Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000003367 polycyclic group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto azabicíclico sustituido de aminometilpiridiloximetilo/bencisoxazol, una composición farmacéutica que comprende el mismo y un método para tratar uno o más trastornos del CNS u otros, que incluye el tratamiento concurrente de trastornos como esquizofrenia y depresión. Reivindicación 1: Un compuesto, caracterizado porque tiene la fórmula (1) o su enantiómero (R) o (S), o sus isómeros cis o trans, o una sal, solvato o profármaco farmacéuticamente aceptable del mismo o de cualquiera de los que anteceden, en la que m es 0 o 1; Z es como se muestra en los grupos de fórmulas (2) en donde R7 es H o alcoxi (C1-3); R8 es H, hidroxi o alcoxi (C1-3); y R9 es alcoxi (C1-3); X es O o NR en donde R es H alquilo (C1-6); Y es metileno, en donde n es 0, 1, o 2; u O, N o S, en donde n es 2, 3, o 4; R1 y R2 son cada uno independientemente H, halógeno o un grupo alquilo (C1-6), alcoxi (C1-6) o alcoxi (C1-6)-alquilo(C1-6), y uno cualquiera de estos grupos puede estar sin sustituir o sustituido con uno o más halógenos; R3 y R4 son cada uno independientemente H, un grupo alquilo (C1-6), cicloalquilo (C3-7) o un grupo heterocíclico de 5 o 6 miembros, y uno cualquiera de estos grupos puede estar sin sustituir o sustituido con uno o más de cualquiera de los siguientes: alquilo (C1-4), cicloalquilo (C3-7), alcoxi (C1-4), arilo (C6-10), un grupo heterocíclico de 5 a 6 miembros, amino, halógeno o hidroxi; o R3 y R4 junto con el átomo de N al que están unidos forman: (i) un anillo monocíclico opcionalmente insaturado de 3 a 7 miembros; o (ii) un anillo policíclico opcionalmente insaturado de 4 a 10miembros, en el que dicho anillo monocíclico o policíclico tiene opcionalmente uno o dos heteroátomos adicionales seleccionados entre N, O y S, en donde cualquiera de dichos anillos (i) o (ii) puede estar sin sustituir o sustituido con uno o más grupos alquilo (C1-4), alcoxi (C1-4), alcoxi (C1-4)-alquilo (C1-4), cicloalquilo (C3-7), arilo (C6-10), aralquilo (C7-13), heteroarilo de 5 a 10 miembros, hidroxi, amino, ciano o halógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45392503P | 2003-03-12 | 2003-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043537A1 true AR043537A1 (es) | 2005-08-03 |
Family
ID=32990837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100770A AR043537A1 (es) | 2003-03-12 | 2004-03-10 | Derivados azabiciclicos de piridiloximetilo y bencisoxazol |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7345038B2 (es) |
| EP (1) | EP1608648B1 (es) |
| JP (2) | JP3910627B2 (es) |
| KR (2) | KR100767854B1 (es) |
| CN (1) | CN100389115C (es) |
| AP (1) | AP2005003390A0 (es) |
| AR (1) | AR043537A1 (es) |
| AU (2) | AU2004220327B2 (es) |
| BR (1) | BRPI0408248A (es) |
| CA (1) | CA2518740C (es) |
| EA (1) | EA009527B1 (es) |
| EC (1) | ECSP056011A (es) |
| GT (1) | GT200400041A (es) |
| HR (1) | HRP20050798A2 (es) |
| IL (1) | IL170290A (es) |
| MA (1) | MA27747A1 (es) |
| MX (1) | MXPA05009660A (es) |
| NL (1) | NL1025710C2 (es) |
| NO (1) | NO20054095L (es) |
| OA (1) | OA13038A (es) |
| PA (1) | PA8597501A1 (es) |
| PE (1) | PE20041057A1 (es) |
| PL (1) | PL378749A1 (es) |
| RS (1) | RS20050692A (es) |
| TN (1) | TNSN05224A1 (es) |
| TW (1) | TW200502234A (es) |
| UA (1) | UA78437C2 (es) |
| UY (1) | UY28225A1 (es) |
| WO (1) | WO2004081007A1 (es) |
| ZA (1) | ZA200506373B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6994726B2 (en) * | 2004-05-25 | 2006-02-07 | Calcitec, Inc. | Dual function prosthetic bone implant and method for preparing the same |
| ATE525377T1 (de) | 2003-10-15 | 2011-10-15 | Osi Pharm Inc | Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase |
| BRPI0507250A (pt) * | 2004-01-29 | 2007-06-26 | Pfizer Prod Inc | combinações para tratar desordens do snc |
| EP2308879A1 (en) | 2004-04-02 | 2011-04-13 | OSI Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| EP1791540A2 (en) * | 2004-09-10 | 2007-06-06 | Pfizer Products Incorporated | Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| US20110046144A1 (en) * | 2008-01-18 | 2011-02-24 | Mulvihill Mark J | Imidazopyrazinol derivatives for the treatment of cancers |
| WO2009143051A1 (en) * | 2008-05-19 | 2009-11-26 | Osi Pharmaceuticals, Inc. | Substituted imidazopyr-and imidazotri-azines |
| JP2012524119A (ja) | 2009-04-20 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Ｃ−ピラジン−メチルアミンの調製 |
| WO2010129740A1 (en) * | 2009-05-07 | 2010-11-11 | Osi Pharmaceuticals, Inc. | Use of osi-906 for treating adrenocortical carcinoma |
| JP2013540145A (ja) * | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2016115282A1 (en) * | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| EP4429465A1 (en) | 2021-11-10 | 2024-09-18 | Symrise AG | Compositions comprising trpm8 agonistic cooling agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008148A1 (en) | 1989-01-23 | 1990-07-26 | Pfizer Inc. | Bis-aza-bicyclic anxiolytic agents |
| US5167034A (en) * | 1990-06-18 | 1992-11-24 | International Business Machines Corporation | Data integrity for compaction devices |
| US5157034A (en) | 1991-02-27 | 1992-10-20 | Pfizer Inc. | Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines |
| DK0607163T3 (da) | 1991-09-25 | 1997-03-17 | Pfizer | Neuroleptiske 2-substituerede perhydro-1-H-pyrido- 1,2-a pyraziner |
| ATE185565T1 (de) | 1992-06-16 | 1999-10-15 | Pfizer | Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica |
| US5731307A (en) | 1994-09-30 | 1998-03-24 | Pfizer, Inc. | Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines |
| CN1157392C (zh) | 1997-05-30 | 2004-07-14 | 神经研究公司 | 在尼古丁ach受体上作为胆碱能配体的8-氮杂双环(3,2,1)辛-2-烯以及辛烷衍生物 |
| PA8469101A1 (es) * | 1998-04-09 | 2000-09-29 | Pfizer Prod Inc | Ligandos azabiciclicos de receptores 5ht1 |
| HUP0104766A3 (en) | 1998-08-26 | 2002-08-28 | Aventis Pharma Ltd West Mallin | Aza-bicycles which modulate the inhibition of cell adhesion and medicaments containing them |
| CA2344249A1 (en) | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | Pyrrolopyrimidines as protein kinase inhibitors |
| CZ2001959A3 (cs) | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidiny jako inhibitory kinasy |
| UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| CN1156452C (zh) | 1999-03-12 | 2004-07-07 | 贝林格尔·英格海姆药物公司 | 作为消炎剂的化合物 |
| EP1177792A3 (en) * | 2000-07-27 | 2002-10-23 | Pfizer Products Inc. | Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
-
2004
- 2004-02-23 EP EP04713592A patent/EP1608648B1/en not_active Expired - Lifetime
- 2004-02-23 JP JP2006506261A patent/JP3910627B2/ja not_active Expired - Fee Related
- 2004-02-23 BR BRPI0408248-6A patent/BRPI0408248A/pt not_active IP Right Cessation
- 2004-02-23 CA CA2518740A patent/CA2518740C/en not_active Expired - Fee Related
- 2004-02-23 RS YUP-2005/0692A patent/RS20050692A/sr unknown
- 2004-02-23 KR KR1020057016859A patent/KR100767854B1/ko not_active Expired - Fee Related
- 2004-02-23 UA UAA200508639A patent/UA78437C2/uk unknown
- 2004-02-23 OA OA1200500259A patent/OA13038A/en unknown
- 2004-02-23 WO PCT/IB2004/000499 patent/WO2004081007A1/en not_active Ceased
- 2004-02-23 HR HR20050798A patent/HRP20050798A2/hr not_active Application Discontinuation
- 2004-02-23 PL PL378749A patent/PL378749A1/pl not_active Application Discontinuation
- 2004-02-23 AU AU2004220327A patent/AU2004220327B2/en not_active Ceased
- 2004-02-23 MX MXPA05009660A patent/MXPA05009660A/es active IP Right Grant
- 2004-02-23 AP AP2005003390A patent/AP2005003390A0/xx unknown
- 2004-02-23 KR KR1020077013527A patent/KR20070074667A/ko not_active Withdrawn
- 2004-02-23 CN CNB2004800066516A patent/CN100389115C/zh not_active Expired - Fee Related
- 2004-02-23 EA EA200501148A patent/EA009527B1/ru not_active IP Right Cessation
- 2004-03-08 PA PA20048597501A patent/PA8597501A1/es unknown
- 2004-03-09 PE PE2004000256A patent/PE20041057A1/es not_active Application Discontinuation
- 2004-03-10 AR ARP040100770A patent/AR043537A1/es not_active Application Discontinuation
- 2004-03-11 UY UY28225A patent/UY28225A1/es not_active Application Discontinuation
- 2004-03-11 GT GT200400041A patent/GT200400041A/es unknown
- 2004-03-11 TW TW093106481A patent/TW200502234A/zh unknown
- 2004-03-12 NL NL1025710A patent/NL1025710C2/nl not_active IP Right Cessation
- 2004-03-12 US US10/800,328 patent/US7345038B2/en not_active Expired - Fee Related
-
2005
- 2005-08-10 ZA ZA200506373A patent/ZA200506373B/en unknown
- 2005-08-15 IL IL170290A patent/IL170290A/en not_active IP Right Cessation
- 2005-09-02 NO NO20054095A patent/NO20054095L/no unknown
- 2005-09-12 EC EC2005006011A patent/ECSP056011A/es unknown
- 2005-09-12 TN TNP2005000224A patent/TNSN05224A1/fr unknown
- 2005-09-12 MA MA28495A patent/MA27747A1/fr unknown
-
2006
- 2006-10-26 JP JP2006291545A patent/JP2007051155A/ja active Pending
-
2010
- 2010-07-23 AU AU2010203303A patent/AU2010203303A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043537A1 (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol | |
| PE20250021A1 (es) | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| PE20252338A1 (es) | Compuesto agonista de receptor thrb y metodo de preparacion | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR079634A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR061867A1 (es) | Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR051092A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa | |
| AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| CO6150158A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y su uso | |
| AR063147A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central. | |
| PE20242099A1 (es) | Compuestos de piridotriazina sustituidos y usos de estos | |
| ES2195933T3 (es) | Nuevos derivados de flavonas, xantonas y cumarinas. | |
| AR050435A1 (es) | DERIVADOS DE HIDROXIAMIDA, PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS. | |
| AR056613A1 (es) | Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen | |
| AR050281A1 (es) | Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas | |
| CO5590916A2 (es) | Dicetopiperacinas sustituidas como antagonistas de oxitocina | |
| AR067975A1 (es) | Derivados de la n-bencil, n-arilcarbonilpiperazina | |
| AR075531A1 (es) | Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros | |
| CO5601021A2 (es) | Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure |